Related Experiment Video
Updated: Feb 6, 2026

Exploring the Potential of Mesenchymal Stem Cell Sheet on The Development of Hepatocellular Carcinoma In Vivo
Published on: September 11, 2018
Metformin reverses stem cell‑like HepG2 sphere formation and resistance to sorafenib by attenuating
Yan Feng1, Xing Guo1, Xinping Huang1
1Research Department, Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Abstract:
Cancer stem cells (CSCs) have been reported to be associated with the recurrence and drug resistance of liver cancer. In the present study, stem cell‑like HepG2 cell spheres were enriched using stem cell conditioned culture medium. As expected, stem‑like HepG2 cell spheres exhibited increased resistance to sorafenib. Metformin, a common drug used to treat type 2 diabetes mellitus, reduced the diameters and numbers of stem‑like HepG2 spheres, and increased their sensitivity to sorafenib. Western blotting confirmed that low doses of metformin reversed the epithelial‑mesenchymal transformation (EMT) process of HepG2 spheres. These results suggested that metformin enhanced sensitivity to sorafenib, which was probably through reversal of the EMT process of sphere‑forming cells and by reducing the formation of CSCs.
Insights
Metformin can overcome drug resistance in liver cancer by targeting cancer stem cells (CSCs). This study shows metformin reduces CSCs and enhances sorafenib sensitivity, likely by reversing epithelial-mesenchymal transformation (EMT).
Area of Science:
- Hepatocellular carcinoma research
- Cancer stem cell biology
- Pharmacology
Background:
- Cancer stem cells (CSCs) are implicated in liver cancer recurrence and drug resistance.
- HepG2 cell spheres, enriched for stem-like properties, display resistance to sorafenib.
Purpose of the Study:
- To investigate the effect of metformin on CSC-like HepG2 spheres.
- To determine if metformin can re-sensitize these cells to sorafenib.
Main Methods:
- Enrichment of stem cell-like HepG2 spheres using conditioned medium.
- Treatment of spheres with metformin and sorafenib.
- Assessment of sphere formation, size, and drug sensitivity.
- Western blotting to analyze epithelial-mesenchymal transformation (EMT) markers.
Main Results:
- Stem-like HepG2 spheres showed increased resistance to sorafenib.
- Metformin reduced the number and size of these spheres.
- Metformin increased the sensitivity of HepG2 spheres to sorafenib.
- Low-dose metformin reversed the EMT process in HepG2 spheres.
Conclusions:
- Metformin enhances sorafenib sensitivity in liver cancer.
- This effect is likely mediated by the reversal of EMT and reduction of CSCs.
- Metformin shows potential as an adjuvant therapy for liver cancer.
More Related Videos
Related Concept Videos
Mesenchymal Stem Cells
Zygotic Development And Stem Cell Formation
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Bacterial Transformation
Griffith made an unexpected discovery when he killed the pathogenic strain and mixed its remains with the live, non-pathogenic strain. Not only did the mixture kill host mice, but it also contained living pathogenic bacteria that...
Adult Stem Cells
Embryonic Stem Cells

